Internal Medicine, Infectious Disease · New Orleans, LA
NPI
1184060618
Since 2013
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1514 Jefferson Hwy
New Orleans, LA, 70121
Phone (504) 842-4005
Groups this clinician bills Medicare through
Medicare paid, 2024
$16K
205 services
Medicare patients, 2024
99
Average age 69
Drug cost, 2024
$1.5M
1,193 prescriptions
Company payments, 2025
$0
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Poppy Markwell was code 99232 (hospital e&m - subsequent), 71 times for 41 patients. In total Poppy Markwell billed 205 services in 14 codes, and Medicare paid $16K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-08-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 71 | 41 | $60.24 | $4,277 |
| 99222 Hospital E&M - Initial | Facility | 28 | 28 | $92.83 | $2,599 |
| 99233 Hospital E&M - Subsequent | Facility | 28 | 23 | $90.68 | $2,539 |
| 99214 Office E&M - Established | Facility | 26 | 21 | $63.25 | $1,645 |
| 99223 Hospital E&M - Initial | Facility | 16 | 16 | $129.19 | $2,067 |
By year: 2022 $22K for 246 services; 2023 $21K for 244 services; 2024 $16K for 205 services.
Medicare prescription drug claims, 2024
In 2024, the drug Poppy Markwell prescribed most often to Medicare patients was Azithromycin, with 139 prescriptions and refills. In total Poppy Markwell wrote 1,193 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Azithromycin Generic | 139 | 187 | 35 | $3,193 |
| Ethambutol Hcl Generic | 118 | 169 | 26 | $7,002 |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 94 | 94 | 11 | $367K |
| Teflaro Ceftaroline Fosamil Acetate | 78 | 78 | Under 11 | $138K |
| Rifampin Generic | 76 | 100 | 16 | $3,330 |
| Daptomycin Generic | 54 | 54 | 11 | $51K |
| Amikacin Sulfate Generic | 53 | 53 | Under 11 | $1,526 |
| Imipenem-Cilastatin Sodium Imipenem/Cilastatin Sodium | 50 | 50 | Under 11 | $33K |
| Cefadroxil Generic | 47 | 49 | Under 11 | $1,135 |
| Doxycycline Hyclate Generic | 41 | 46 | 16 | $1,002 |
| Ceftriaxone Ceftriaxone Sodium | 35 | 35 | 12 | $1,216 |
| Tivicay Dolutegravir Sodium | 33 | 33 | Under 11 | $70K |
| Arikayce Amikacin Liposomal/Neb.Accessr | 24 | 24 | Under 11 | $366K |
| Fluconazole Generic | 24 | 27 | Under 11 | $1,017 |
| Dovato Dolutegravir Sodium/Lamivudine | 21 | 21 | Under 11 | $60K |
Brand drugs: 357 claims; generic drugs: 836 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Poppy Markwell $0 (- in general payments such as food, travel and fees) from 1 company.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.